This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J.Cost-effectiveness analyses of natalizumab (tysabri Rm) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. PharmacoEconomics 26: 617-627, No. 7, 2008
About this article
Cite this article
Natalizumab for keeping patients out of HARRMS way?. Pharmacoecon. Outcomes News 557, 4 (2008). https://doi.org/10.2165/00151234-200805570-00008
- Public Health
- Multiple Sclerosis
- Health Outcome
- Cost Effectiveness